Aptitude Receives FDA 510(k) Clearance for Next-Generation Metrix COVID Test with 3x Sensitivity
Published · Updated
Cited: San Francisco Chronicle, PR Newswire, Clinical Lab Products
TL;DR
Aptitude Medical Systems received FDA 510(k) clearance for its next-generation Metrix COVID test, which offers three times higher sensitivity and 30% faster results than its EUA predecessor, ahead of the December 2026 EUA termination deadline.
Why now
COVID-19 continues to surge, and the FDA is winding down emergency use authorizations. Aptitude’s clearance ensures that clinics and consumers have a clinical-grade molecular test that meets traditional regulatory standards, filling a gap as weaker home rapid tests struggle with accuracy.
Agree / conflict
While the Metrix test’s improved sensitivity is a clear win for point-of-care diagnostics, some may argue that at-home rapid tests remain more accessible and affordable for the masses. The two serve different needs rather than direct competition.
Takeaway
For individuals seeking reliable COVID-19 testing at urgent care or at home, the Metrix platform provides a new, highly sensitive option that will remain available beyond the EUA transition period.
Aptitude Medical Systems has secured FDA 510(k) clearance for its next-generation Metrix COVID test, a handheld molecular diagnostic that triples sensitivity and cuts result times by 30% compared to its emergency-authorized predecessor. The clearance is the first traditional approval for the Metrix platform and comes as the FDA transitions COVID-19 tests from emergency use to permanent status before the December 2026 deadline. The device, supported by BARDA, is cleared for both over-the-counter and professional CLIA-waived use, making lab-quality testing practical in settings like urgent care clinics that previously lacked such capabilities.
Aptitude is simultaneously pushing a Metrix COVID/Flu combo test through FDA review and building a broader menu targeting RSV, Strep, and sexually transmitted infections. Hundreds of urgent care providers have already adopted the system, underscoring demand for compact, high-performance molecular diagnostics. While home rapid tests remain a staple for convenience, the Metrix platform aims to bridge the gap where accuracy and speed are paramount.
FAQ
What is the main improvement of the new Metrix COVID test?
The next-generation Metrix test offers approximately three times greater analytical sensitivity and delivers results 30% faster than the original EUA-version.
Where can the Metrix test be used?
It is FDA-cleared for both over-the-counter at-home use and professional use in CLIA-waived settings such as urgent care clinics and physician offices.
Why is this clearance happening now?
The FDA is transitioning COVID-19 tests from emergency use authorizations (EUAs) to standard 510(k) clearance. The COVID-19 EUA declarations for medical devices are set to terminate on December 26, 2026.
Will the Metrix platform offer other tests besides COVID?
Yes, Aptitude is developing a Metrix COVID/Flu test currently under FDA review, and additional tests for RSV, Strep, and sexually transmitted infections are in late-stage development.
How does this affect home rapid tests?
Home rapid tests remain a convenient and widely used option. The Metrix test offers higher sensitivity and is designed for settings where greater accuracy and faster results are needed, such as urgent care.
Sources
Canonical URL: /trend/2026/aptitude-receives-fda-510-k-clearance-for-next-generation-metrix-covid-test-with
Disclaimer
Digests summarize public sources. They are not advice, forecasts, or a complete record of every trend.
This digest was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This digest may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.